PolyQ disease: too many Qs, too much function?

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Polyglutamine (polyQ) diseases are a class of inherited neurodegenerative disorders characterized by the expansion of CAG repeats in specific genes.
• The gain-of-function toxicity mechanism underlying polyQ diseases has been a long-standing area of research and debate.
• Understanding the precise molecular events leading to neuronal dysfunction and death is crucial for therapeutic development.

Discussion:

• Duvick et al. and Nedelsky et al. present findings that challenge previous assumptions about polyQ disease pathogenesis.
• Their studies indicate that the normal function of the expanded polyglutamine proteins, rather than a novel toxic function, is responsible for the observed pathology.
• This suggests that interventions targeting the aberrant gain-of-function may not be the sole therapeutic avenue.

Key Insights:

• Pathology in two polyglutamine diseases is mediated by the normal activity of the affected proteins.
• This finding shifts the focus from solely toxic gain-of-function to the consequences of altered normal protein function.
• The research provides a new framework for understanding the molecular basis of polyglutamine-mediated neurodegeneration.

Outlook:

• Future research should explore how normal protein activity becomes toxic when polyglutamine tracts are expanded.
• Therapeutic strategies may need to consider modulating the normal function of polyQ proteins, not just inhibiting toxic gain-of-function.
• These findings have broad implications for understanding other proteinopathies and developing effective treatments for neurodegenerative diseases.